- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03070353
Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury
February 28, 2017 updated by: Abhasnee Sobhonslidsuk, Ramathibodi Hospital
A pilot study of Dextran-40 infusion in patients with decompensated cirrhosis presenting with AKI
Study Overview
Detailed Description
A pilot study of Dextran-40 infusion in decompensated cirrhotic patients complicating with AKI.
Dextran-40® was administered at 1 g/kg/day for two days.
AKI reversal was defined when serum creatinine was < 1.5 mg/dL.
Albumin infusion was given if AKI reversal did not occur.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 2
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Decompensated cirrhosis with acute kidney injury
- Ager over 18 years old
Exclusion Criteria:
- Having chronic kidney disease, severe heart or lung disease, severe sepsis
- Pregnant
- Receiving nephrotoxic agents
- Having history of allergic to Dextran
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dextran 40
Dextran 40 infusion
|
Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AKI reversal
Time Frame: 2 weeks
|
Reducing creatinine to below 1.5 mg/dl
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: 1 year
|
Death
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Abhasnee Sobhonslidsuk, MD, Ramathibodi Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2015
Primary Completion (Actual)
June 30, 2016
Study Completion (Actual)
June 30, 2016
Study Registration Dates
First Submitted
February 28, 2017
First Submitted That Met QC Criteria
February 28, 2017
First Posted (Actual)
March 3, 2017
Study Record Updates
Last Update Posted (Actual)
March 3, 2017
Last Update Submitted That Met QC Criteria
February 28, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ID 11-57-21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
IPD will be provided if directly contact with investigator
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AKI
-
Chulalongkorn UniversityRecruiting
-
Renibus Therapeutics, Inc.CompletedAKIUnited States, Australia, Canada
-
Phramongkutklao College of Medicine and HospitalUnknown
-
University of Colorado, DenverCompleted
-
Hospital Universitari de BellvitgeFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauCompleted
-
The University of Texas Medical Branch, GalvestonRecruitingContrast-induced Acute Kidney Injury (CI-AKI) Following Coronary Angiogram (CI-AKI) | Contrast-induced Nephropathy Following Coronary Angiogram (CIN)United States
-
Qure Healthcare, LLCHikari DXCompletedAKI | Contrast-induced NephropathyUnited States
-
Santersus AGCompletedSepsis | Sepsis-associated AKIRussian Federation
-
Zhongnan HospitalUnknown
Clinical Trials on Dextran 40
-
BioMarin PharmaceuticalCompletedPhenylketonuria (PKU)United States
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingType 2 Diabetes Mellitus | Diabetic Kidney Disease | Adolescent Obesity | Puberty | Pre Diabetes | Kidney HypoxiaUnited States
-
NestléCompletedPostprandial Glucose ResponseSwitzerland
-
University of Colorado, DenverEnrolling by invitationObesity | Diabetic Kidney Disease | Diabetic Nephropathies | Type 2 Diabetes | Adolescent Obesity | Nephropathy | Diabetes Type 2United States
-
Woman's Health University Hospital, EgyptCompletedIron Deficiency AnemiaEgypt
-
The University of Texas Medical Branch, GalvestonCompletedAnemia, Iron Deficiency | Delivery ComplicationUnited States
-
Auerbach Hematology Oncology Associates P CPharmacosmos A/SCompletedPregnancyUnited States
-
Shanghai East HospitalUnknownChemotherapy-induced AnaemiaChina
-
Hospital Civil de GuadalajaraActive, not recruitingAcute Kidney Injury | Anemia, Iron DeficiencyMexico
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingCritical Illness | AnemiaUnited States